Cipla stock in focus after Q2 PAT beats estimates. Should you buy, sell or hold?
Cipla's shares will be in focus during Wednesday's trading after the company posted a 15% growth in its consolidated net profit, reaching Rs 1,303 crore for the quarter ended September 2024, compared to Rs 1,131 crore in the year-ago period. The profit exceeded the ET Now poll estimates of Rs 1,218 crore.
Revenue from operations rose 6% year-on-year (YoY) to Rs 7,051 crore in the July-September 2024 period, compared to Rs 6,678 crore in the same period last year. The company reported an EBITDA growth of 12% YoY, reaching Rs 1,886 crore in the second quarter.
Cipla's India business grew by 5% YoY during the quarter. The Branded Prescription business continued to outpace the market in key chronic therapies.
However, the overall segment experienced slow growth during the quarter, primarily due to a slowdown in the anti-infectives market, one of its largest therapies, which grew by only 4.9%, compared to over 12% growth last year. Nevertheless, chronic therapies such as respiratory, cardiac, and urology continued to outpace market growth.
Should you buy or sell Cipla's stock? Here’s what analysts say:
Stock Trading
Candlesticks Made Easy: Candlestick Pattern Course
By — elearnmarkets, Financial Education by StockEdge
Stock Trading
Options Scalping Made Easy
By — Sivakumar Jayachandran, Ace Scalper
Stock Trading
ROC Made Easy: Master Course for ROC Stock Indicator
By — Souradeep Dey, Equity and Commodity Trader, Trainer
Stock Trading
Options Trading Made Easy: Options Trading Course
By — Anirudh Saraf, Founder- Saraf A &
